Document Type
Response or Comment
Publication Date
2021
ISSN
1537-6591
Publisher
Oxford University Press
Language
en-US
Abstract
TO THE EDITOR—Rome and Kesselheim [1] claimed that rewarding developers of novel antibiotics with transferable exclusivity vouchers is an expensive approach to promoting antibiotic development. This analysis is incomplete as it focuses only on the cost of bringing new antibiotics to market without acknowledging their societal value. The authors also did not suggest an alternative approach. With patients running out of treatment options for resistant infections, failing to strengthen the antibiotic pipeline is not a reasonable option.
Recommended Citation
Helen Boucher, Thomas M. File, Vance Fowler, Amanda Jezek, John Rex & Kevin Outterson,
Antibiotic Development Incentives That Reflect Societal Value of Antibiotics
,
72
Clinical Infectious Diseases
e420
(2021).
Available at:
https://doi.org/https://doi.org/10.1093/cid/ciaa092
